KR20170031653A - 지질 축적 장애의 치료를 위한 방법 및 조성물 - Google Patents

지질 축적 장애의 치료를 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20170031653A
KR20170031653A KR1020167032127A KR20167032127A KR20170031653A KR 20170031653 A KR20170031653 A KR 20170031653A KR 1020167032127 A KR1020167032127 A KR 1020167032127A KR 20167032127 A KR20167032127 A KR 20167032127A KR 20170031653 A KR20170031653 A KR 20170031653A
Authority
KR
South Korea
Prior art keywords
cells
npc1
pkc
bryostatin
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167032127A
Other languages
English (en)
Korean (ko)
Inventor
이안니스 에이 이오안노우
로렌스 앨트스틸
데이비드 알 크록포드
사타파나 콩사무트
Original Assignee
뉴로트롭 바이오싸이언스 인크.
이칸 스쿨 오브 메디슨 엣 마운트 시나이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뉴로트롭 바이오싸이언스 인크., 이칸 스쿨 오브 메디슨 엣 마운트 시나이 filed Critical 뉴로트롭 바이오싸이언스 인크.
Publication of KR20170031653A publication Critical patent/KR20170031653A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
KR1020167032127A 2014-04-18 2015-04-14 지질 축적 장애의 치료를 위한 방법 및 조성물 Withdrawn KR20170031653A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461981473P 2014-04-18 2014-04-18
US61/981,473 2014-04-18
US201461987360P 2014-05-01 2014-05-01
US61/987,360 2014-05-01
PCT/US2015/025821 WO2015160851A1 (en) 2014-04-18 2015-04-14 Methods and compositions for treatment of lipid storage disorders

Publications (1)

Publication Number Publication Date
KR20170031653A true KR20170031653A (ko) 2017-03-21

Family

ID=54321042

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167032127A Withdrawn KR20170031653A (ko) 2014-04-18 2015-04-14 지질 축적 장애의 치료를 위한 방법 및 조성물

Country Status (9)

Country Link
US (3) US9724328B2 (enExample)
EP (1) EP3131543A4 (enExample)
JP (1) JP2017511387A (enExample)
KR (1) KR20170031653A (enExample)
CN (1) CN107072982A (enExample)
CA (1) CA2946115A1 (enExample)
IL (1) IL248494A0 (enExample)
MX (1) MX2016013680A (enExample)
WO (1) WO2015160851A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018034318A1 (ja) 2016-08-18 2018-02-22 国立大学法人 奈良先端科学技術大学院大学 免疫調節剤
AU2019255739A1 (en) * 2018-04-20 2020-11-12 Biojiva Llc Stabilized polyunsaturated compounds and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256286B2 (en) 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
JP2003515601A (ja) 1999-11-30 2003-05-07 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ ブリオスタチンアナログ、合成方法および使用
WO2004004641A2 (en) 2002-07-02 2004-01-15 Blanchette Rockefeller Neurosciences Institute PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPα SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS
US8497385B2 (en) 2007-08-31 2013-07-30 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
WO2009099563A2 (en) * 2008-02-05 2009-08-13 Blanchette Rockefeller Neurosciences Institute Combination of a nmda receptor channel blocker and a pkc activator for treatment of alzheimer's disease
CA2941035A1 (en) 2008-07-28 2010-02-04 Blanchette Rockefeller Neurosciences Institute Pkc-activating compounds for the treatment of neurodegenerative diseases
US20120156180A1 (en) * 2009-08-10 2012-06-21 The Board Of Trustees Of The University Of Illinois Compositions and methods for the treatment of krabbe and other neurodegenerative diseases
US10821079B2 (en) * 2011-11-13 2020-11-03 Cognitive Research Enterprises, Inc. PKC activators and combinations thereof
WO2015148975A1 (en) * 2014-03-27 2015-10-01 Alkon Daniel L Compositions and methods to treat niemann-pick disease

Also Published As

Publication number Publication date
EP3131543A4 (en) 2017-12-20
US20150297559A1 (en) 2015-10-22
US20190201377A1 (en) 2019-07-04
CN107072982A (zh) 2017-08-18
CA2946115A1 (en) 2015-10-22
US9724328B2 (en) 2017-08-08
WO2015160851A1 (en) 2015-10-22
JP2017511387A (ja) 2017-04-20
EP3131543A1 (en) 2017-02-22
MX2016013680A (es) 2017-07-05
IL248494A0 (en) 2016-12-29
US20170172978A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
Shekh-Ahmad et al. KEAP1 inhibition is neuroprotective and suppresses the development of epilepsy
Renvoisé et al. Reep1 null mice reveal a converging role for hereditary spastic paraplegia proteins in lipid droplet regulation
US20200331875A1 (en) Pkc-activating compounds for the treatment of neurodegenerative diseases
AU2021269396B2 (en) Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
Sassa et al. A shift in sphingolipid composition from C24 to C16 increases susceptibility to apoptosis in HeLa cells
Jacobs et al. Hepatic CTP: phosphocholine cytidylyltransferase-α is a critical predictor of plasma high density lipoprotein and very low density lipoprotein
EP3065733B1 (fr) Composes et compositions comprenant de tels composes pour la prévention ou le traitement des dyslipidémies
Bruce et al. The sphingosine-1-phosphate analog FTY720 reduces muscle ceramide content and improves glucose tolerance in high fat-fed male mice
EP2641891B1 (en) PKC-epsilon ACTIVATOR
US20220110902A1 (en) Methods of treating amyloid-beta peptide diseases
JP6466375B2 (ja) Ｐｋｃ活性化剤を使用した、異常な樹状突起棘に関連した認知障害の治療
CA2985625A1 (en) Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele
US11684599B2 (en) Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
JP2016539098A (ja) 網膜の血管障害を治療又は予防する方法
US20210322414A1 (en) Ffa1 (gpr40) as a therapeutic target for neural angiogenesis diseases or disorders
Airaodion et al. Mechanisms for controlling the synthesis of Lipids–Review
KR20170031653A (ko) 지질 축적 장애의 치료를 위한 방법 및 조성물
WO2015192198A1 (en) Treatment of peroxisome biogenesis disorder
Fu et al. Synergistic roles of acyl‐CoA binding protein (ACBP1) and sterol carrier protein 2 (SCP2) in Toxoplasma lipid metabolism
US20140038186A1 (en) Alzheimer's disease-specific alterations of protein kinase c epsilon (pkc-epsilon) protein levels
Bandet et al. CERT-Dependent ceramide transport, a crucial process in cells
EP3903776A1 (en) Composition for improving cognitive function
SIONG FUNCTION AND REGULATION OF CALCIUM-INDEPENDENT PHOSPHOLIPASE A2 IN THE ATTENUATION OF PAIN IN MICE
Fuentes Plasma Membrane Lipid Therapy: Disruption of Oncogenic Ras Driven Phenotypes by Membrane Targeted Dietary Bioactives (Mtdb)
Radin Sphingolipid Metabolism

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161117

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination